Phibro Animal Health Corporation

Phibro Animal Health Corporation

PAHCNYSE / NASDAQHealthcareMid cap

$33.29-$0.79 (-2.3%)

Last close · Data as of Nov 20, 2026

Market cap
$1.3B
P/E
27.8x
EV / EBITDA
13.8x
Revenue
$1.3B
Net margin
3.7%
ROCE
10.1%

-18.4% over the last year

Phibro Animal Health Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-14.2%
3M
-5.4%
6M
-1.5%
1Y
-18.4%
5Y
+52.8%

52-week range

Day change -$0.79 (-2.3%) from $34 to $33 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PAHC, bought on each weekday since 2021.

News & filings

What Phibro Animal Health filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernDebt is 2.67 times shareholders' equity.

Strengths (1)

  • Return on equity rose from 0.9% to 16.9% between fiscal 2024 and fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.

Read moreShow less

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

Sector
Healthcare
Shares outstanding
40.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.3B
P/E
27.8x
P/B
4.7x
EV / EBITDA
13.8x
EV / Sales
1.6x
P/S
1.0x
52-week high
$59.58
52-week low
$28.52

Profitability

Operating margin
8.5%
Net margin
3.7%
EBITDA margin
11.3%
ROE
16.9%
ROCE
10.1%
ROA
3.5%
Asset turnover
0.95

Growth

Revenue
$1.3B
Revenue growth, 1Y
27.4%
Revenue CAGR, 3Y
11.2%
Net profit growth, 1Y
1897.7%
Free cash flow
$41.8M

Solvency

Current ratio
2.76
Debt / Equity
2.67
Debt / Assets
0.56
CFO / Net profit
1.66
Cash / Market cap
5.7%

Where the revenue went

Of every $100 of FY2025 revenue, $4 was left as net income.

Phibro Animal Health Corporation income statement flow, FY2025
Phibro Animal Health Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$896.3M
RevenueGross profit$399.9M
Gross profitSelling, general and administrative$289.5M
Gross profitOther operating expenses$0.00
Gross profitOperating income$110.5M
Operating incomePretax income$68.0M
Operating incomeInterest and other expense$42.5M
Pretax incomeTax and other$19.7M
Pretax incomeNet income$48.3M

Revenue and net profit

Revenue grew 27.4% in FY2025; net profit is the dashed line.

Phibro Animal Health Corporation revenue and net profit by fiscal year
Phibro Animal Health Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$942.3M$49.2M
FY2023$977.9M$32.6M
FY2024$1.0B$2.4M
FY2025$1.3B$48.3M

Cash flows

FY2025: $80.1M from operations, $41.8M free after investment (dashed).

Phibro Animal Health Corporation operating and free cash flow by fiscal year
Phibro Animal Health Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$31.6M-$5.4M
FY2023$13.3M-$38.5M
FY2024$87.6M$46.4M
FY2025$80.1M$41.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.3B+27.4%1Y
EBITDA
$146.8M+112.6%1Y
Net profit
$48.3M+1,897.7%1Y
Cash from operations
$80.1M-8.5%1Y
Free cash flow
$41.8M-9.8%1Y
Revenue CAGR, 3Y
11.2%
Net profit CAGR, 3Y
-0.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.3B$146.8M$48.3M$41.8M16.9%+27.4%+1897.7%

Monthly returns

Month-by-month returns of PAHC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.4B
Liabilities$1.1B
Equity$285.7M
Paid-in capital$137.0M
Retained earnings$272.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PAHC highlighted.

P/E against peers

PAHC trades at 27.8x earnings against a peer median of 11.9x (a 132% premium).

Not shown (no positive earnings and no EV / Sales): Acadia Healthcare Company, Inc., Neogen Corporation, Sarepta Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Phibro Animal Health CorporationPAHCthis companyP/E ↑ premium$1.3B27.8x4.7x16.9%13.8x
TransMedics Group, Inc.TMDX$2.5B13.0x5.2x40.2%16.8x
Acadia Healthcare Company, Inc.ACHC$2.3B-2.1x1.2x-56.6%-6.5x
Prestige Consumer Healthcare Inc.PBH$2.2B11.3x1.1x10.1%9.5x
LeMaitre Vascular, Inc.LMAT$2.1B37.0x5.4x14.7%25.3x
Select Medical Holdings CorporationSEM$2.0B14.0x1.2x8.6%9.2x
Neogen CorporationNEOG$2.0B-1.8x1.0x-52.7%-2.9x
ADMA Biologics, Inc.ADMA$1.8B12.6x3.9x30.8%9.3x
Sarepta Therapeutics, Inc.SRPT$1.8B-2.5x1.5x-62.5%-3.2x
Peer median—11.9x1.4x9.3%9.3x

Year-to-date ROI

PAHC since 1 January, against earlier years.

Historical volatility

PAHC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Phibro Animal Health Corporation operating margin by fiscal year
Phibro Animal Health Corporation operating margin by fiscal year
DateOperating margin
FY20228.4%
FY20237.3%
FY20245.2%
FY20258.5%
LineFY2025
Cost of revenueCost Of Revenue$896.3M
Gross profitGross Profit$399.9M
Operating expensesOperating Expense$289.5M
Selling, general and administrativeSelling General And Administration$289.5M
Total expensesTotal Expenses$1.2B
Pretax incomePretax Income$68.0M

Learn while you research

Academy chapters picked for Phibro Animal Health Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing27% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Leverage RatiosDebt/Equity of 2.67 is elevated, understand what that means for solvency.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →